AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23327030 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine + fentanyl (7.5 mg of 0.5% bupivacaine + 15 microg fentanyl intrathecally)
Number of subjects: 50
Study 23327030 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine + fentanyl (7.5 mg of 0.5% levobupivacaine + 15 microg fentanyl intrathecally)
Number of subjects: 50
Study 20039889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily
Number of subjects: 22
Study 20039889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18786043 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education delivered by lay health educators (LHEs)
Number of subjects: 183
Study 18786043 — intervention group
Group type: COMPARATOR
Intervention: General health promotion education (attention-control condition)
Number of subjects: 183
Study 16258155 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time polymerase chain reaction (PCR) assay targeting 16S rDNA, limit of detection: 40, 50, or 2000 CFU/ml for E. coli, group B Streptococcus, and Listeria monocytogenes respectively, sample preparation and PCR duration less than 4 hours.
Number of subjects: 85
Study 16258155 — intervention group
Group type: COMPARATOR
Intervention: Culture-based methods for diagnosing neonatal sepsis, duration 1 to 2 days for growth detection, 5 days for no-growth results.
Number of subjects: 85
Study 12518175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve blocks
Number of subjects: 68
Study 12518175 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 68
Study 9951493 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA) 75 mg/kg per day divided into 3 doses
Number of subjects: 238
Study 9951493 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 0.75 mg/kg per day divided into 2 doses
Number of subjects: 238
Study 9951493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 7591596 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg/day) for 72 weeks
Number of subjects: 64
Study 7591596 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (4 mg/day) for 24 weeks
Number of subjects: 64
Study 2309643 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental feeding from birth to age 36 months
Number of subjects: 0
Study 2309643 — intervention group
Group type: COMPARATOR
Intervention: Control (unsupplemented)
Number of subjects: 0
Study 6246006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecillinam alone or in combination with ampicillin
Number of subjects: 20
Study 6246006 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin alone
Number of subjects: 20
Study 6246006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecillinam (5 mg/kg intravenously every six hours)
Number of subjects: 20
Study 6246006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecillinam (10 mg/kg intravenously every six hours)
Number of subjects: 20
Study 6246006 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (mecillinam and ampicillin)
Number of subjects: 20
Study 31074244 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (PD-1 inhibitor) administered every second week until disease progression
Number of subjects: 18
Study 31074244 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (PD-1 inhibitor)
Number of subjects: 18
Study 30201024 — intervention group
Group type: EXPERIMENTAL
Intervention: BHH10
Number of subjects: 168
Study 30201024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 27125883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fibre (5 g b.d. for 4 weeks)
Number of subjects: 72
Study 27125883 — intervention group
Group type: COMPARATOR
Intervention: Psyllium (5 g b.d. for 4 weeks)
Number of subjects: 72
Study 27125883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fibre
Number of subjects: 72
Study 27125883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fibre and psyllium
Number of subjects: 72
Study 25453515 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 12
Study 25453515 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 12
Study 23448082 — intervention group
Group type: EXPERIMENTAL
Intervention: New specially engineered sonic powered toothbrush
Number of subjects: 184
Study 23448082 — intervention group
Group type: COMPARATOR
Intervention: Commercially available toothbrushes
Number of subjects: 184
Study 20490392 — intervention group
Group type: EXPERIMENTAL
Intervention: Esthet‐X Flow
Number of subjects: 63
Study 20490392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Flow
Number of subjects: 63
Study 20490392 — intervention group
Group type: COMPARATOR
Intervention: Both materials
Number of subjects: 63
Study 18931210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein Entry Indicator Device (VEID)
Number of subjects: 202
Study 18931210 — intervention group
Group type: COMPARATOR
Intervention: Control (standard peripheral venous cannulation)
Number of subjects: 202
Study 15531619 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow via sponge-tipped oxygen catheter at a rate of 115 ml kg(‐1) min(‐1) for 6 hours
Number of subjects: 15
Study 15531619 — intervention group
Group type: COMPARATOR
Intervention: No airflow for 6 hours (control)
Number of subjects: 15
Study 12953342 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg qid for 3 days
Number of subjects: 0
Study 12953342 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg bid for 3 days
Number of subjects: 0
Study 12953342 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg qid
Number of subjects: 0
Study 12953342 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg bid
Number of subjects: 0
Study 10971231 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and metronidazole 500 mg b.d. (PCM)
Number of subjects: 331
Study 10971231 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg b.d., amoxycillin 1000 mg b.d., and clarithromycin 500 mg b.d. (PAC)
Number of subjects: 331
Study 9011466 — intervention group
Group type: COMPARATOR
Intervention: 3 MU interferon-alpha2b every two days for another six months (group A, total dose: 410 MU)
Number of subjects: 138
Study 9011466 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of interferon-alpha2b (6 MU every two days for three months, followed by 10 MU every two days for three months) (group B, total dose: 870 MU)
Number of subjects: 138
Study 9011466 — intervention group
Group type: COMPARATOR
Intervention: 3 MU interferon-alpha2b every two days for three months (initial treatment)
Number of subjects: 138
Study 1434681 — intervention group
Group type: EXPERIMENTAL
Intervention: Zea mays
Number of subjects: 0
Study 1434681 — intervention group
Group type: EXPERIMENTAL
Intervention: Imperata cylindrica
Number of subjects: 0
Study 1434681 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantago major
Number of subjects: 0
Study 1434681 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosiphon stamineus
Number of subjects: 0
Study 1434681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3873614 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 160
Study 3873614 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 160
Study 30696903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine with higher dosage and extended schedule (four monthly doses)
Number of subjects: 179
Study 30696903 — intervention group
Group type: COMPARATOR
Intervention: Standard dosage of dihydroartemisinin-piperaquine
Number of subjects: 179
Study 27836982 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB+SN+NRT
Number of subjects: 5290
Study 27836982 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB+SN
Number of subjects: 5290
Study 27836982 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB+NRT
Number of subjects: 5290
Study 27836982 — intervention group
Group type: COMPARATOR
Intervention: WEB
Number of subjects: 5290
Study 26454450 — intervention group
Group type: EXPERIMENTAL
Intervention: Make a Wish intervention
Number of subjects: 66
Study 26454450 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 66
Study 24099152 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day
Number of subjects: 112
Study 24099152 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.6 mg/day
Number of subjects: 112
Study 22687174 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal meta-stereotype manipulations (your partner thinks you are biased)
Number of subjects: 0
Study 22687174 — intervention group
Group type: COMPARATOR
Intervention: General threat condition
Number of subjects: 0
Study 19367282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomeguatrib 40 mg, b.i.d. for 10 days with temozolomide 75 mg m(‐2) on days 1‐5
Number of subjects: 32
Study 19367282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomeguatrib extended dosing
Number of subjects: 32
Study 19367282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomeguatrib with temozolomide
Number of subjects: 32
Study 17441794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 333
Study 17441794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 333
Study 17441794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 15823785 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginative and hypnotic suggestions
Number of subjects: 60
Study 15823785 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (administered after suggestions)
Number of subjects: 60
Study 15823785 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 60
Study 12516678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare Elite toothbrush
Number of subjects: 25
Study 12516678 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Oral-B 35)
Number of subjects: 25
Study 9595919 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 micrograms/day for three weeks with MAP 10 mg orally for 10 days
Number of subjects: 88
Study 9595919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 7700744 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week multifaceted AIDS education program
Number of subjects: 189
Study 2403699 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived wound healing formula (PDWHF)
Number of subjects: 32
Study 2403699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2403699 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived wound healing formula (PDWHF) after crossover
Number of subjects: 32
Study 678495 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0% levamisole solutions
Number of subjects: 4
Study 678495 — intervention group
Group type: COMPARATOR
Intervention: 3.0% mebendazole suspensions
Number of subjects: 4
Study 678495 — intervention group
Group type: COMPARATOR
Intervention: 0.03% DEC
Number of subjects: 4
Study 30641807 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Comprehensive Care Model (DCCM) intervention implemented by mobile diabetes care teams, four times over one year.
Number of subjects: 100
Study 30641807 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 100
Study 29068977 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope (GS) video laryngoscope
Number of subjects: 45
Study 29068977 — intervention group
Group type: COMPARATOR
Intervention: CTrach laryngeal mask airway (LMA)
Number of subjects: 45
Study 29068977 — intervention group
Group type: COMPARATOR
Intervention: Shikani optical stylet rigid laryngoscope (SOS)
Number of subjects: 45
Study 25865433 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved body image
Number of subjects: 154
Study 25865433 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher exercise intrinsic motivation
Number of subjects: 154
Study 25865433 — intervention group
Group type: EXPERIMENTAL
Intervention: High exercise autonomous motivation
Number of subjects: 154
Study 25865433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower perceived exercise barriers among women with lower autonomous motivation
Number of subjects: 154
Study 25158710 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate brachytherapy (2 × 6 Gy administered in two fractions: first within 4 hours after surgery and second within 24 hours)
Number of subjects: 43
Study 25158710 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate brachytherapy
Number of subjects: 43
Study 22067244 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CC) - 5 minutes of passive rest
Number of subjects: 16
Study 22067244 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Stretching Condition (PSC) - 5 minutes of passive static stretching
Number of subjects: 16
Study 22067244 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Stretching Condition (ASC) - 5 minutes of active static stretching
Number of subjects: 16
Study 22067244 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching Condition (DC) - 5 minutes of dynamic stretching
Number of subjects: 16
Study 19486654 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible clinical depression at initial PSA testing (n=519)
Number of subjects: 4886
Study 19486654 — intervention group
Group type: COMPARATOR
Intervention: Initial psychological distress scores
Number of subjects: 4886
Study 17306006 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii
Number of subjects: 100
Study 17306006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15381932 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg m(‐2) irinotecan as a 90‐min i.v. infusion q3 weeks (Arm A)
Number of subjects: 174
Study 15381932 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg m(‐2) irinotecan as a 90‐min i.v. infusion weekly x 4 weeks q6 weeks (Arm B)
Number of subjects: 174
Study 15381932 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg m(‐2) irinotecan as a 90‐min i.v. infusion q2 weeks (Arm C)
Number of subjects: 174
Study 15381932 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg m(‐2) day(‐1) irinotecan as a 14‐day continuous infusion q3 weeks (Arm D)
Number of subjects: 174
Study 11118782 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic education using a self‐conducted, interactive Kodak Photo‐CD program plus personal drug information and non‐commercial drug leaflets.
Number of subjects: 0
Study 11118782 — intervention group
Group type: COMPARATOR
Intervention: Conventional information (Control group).
Number of subjects: 0
Study 9829706 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO 0.5 g/m2/day
Number of subjects: 45
Study 9829706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9829706 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO
Number of subjects: 45
Study 7510330 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 52
Study 7510330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2687688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg every six hours)
Number of subjects: 6
Study 2687688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7456815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative substitution of factor XIII
Number of subjects: 95
Study 31904995 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense nutrition (1.5 kcal/ml)
Number of subjects: 3957
Study 31904995 — intervention group
Group type: COMPARATOR
Intervention: Routine enteral nutrition (1.0 kcal/ml)
Number of subjects: 3957
Study 31904995 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense nutrition
Number of subjects: 3957
Study 30513266 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol skin cleansing (swab group)
Number of subjects: 170
Study 30513266 — intervention group
Group type: COMPARATOR
Intervention: Control group (cleansed adjacent to injection site)
Number of subjects: 170
Study 30513266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (swab and control)
Number of subjects: 170
Study 27670267 — intervention group
Group type: COMPARATOR
Intervention: Trisodium citrate 30% (TSC)
Number of subjects: 75
Study 27670267 — intervention group
Group type: COMPARATOR
Intervention: Minocycline 3 mg/mL plus EDTA 30 mg/mL (M-EDTA)
Number of subjects: 75
Study 27670267 — intervention group
Group type: COMPARATOR
Intervention: Heparin 1000 IU/mL (H)
Number of subjects: 75
Study 26370664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine contraception (IUD) provided immediately after surgical abortion (18.1%) or at follow-up 2-4 weeks after medical abortion (81.9%).
Number of subjects: 751
Study 26370664 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives prescribed to the control group with follow-up visit advised.
Number of subjects: 751
Study 23701492 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking with graduated compression stockings (GCSs)
Number of subjects: 10
Study 23701492 — intervention group
Group type: COMPARATOR
Intervention: Brisk walking without graduated compression stockings (CON trial)
Number of subjects: 10
Study 22308853 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 48
Study 19056550 — intervention group
Group type: EXPERIMENTAL
Intervention: [6S]‐5‐methylTHF (416 microg/d, 906 nmol/d)
Number of subjects: 69
Study 19056550 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (400 microg/d, 906 nmol/d)
Number of subjects: 69
Study 19056550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 18380203 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 25
Study 18380203 — intervention group
Group type: COMPARATOR
Intervention: Topical 20% aluminum chloride (AC)
Number of subjects: 25
Study 15383083 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotropic incompetence (CI) defined as a failure to achieve 80% of heart rate reserve (%HRR)
Number of subjects: 22
Study 15383083 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body mass index (BMI < 16 kg m(‐2), n = 14)
Number of subjects: 22
Study 15383083 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime HRV parameters reflecting the sympathetic autonomic equilibrium (LF nu, LF/HF ratio)
Number of subjects: 22
Study 15383083 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 22
Study 11324651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (VFE)
Number of subjects: 58
Study 11324651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal Hygiene (VH)
Number of subjects: 58
Study 11324651 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 58
Study 9075480 — intervention group
Group type: EXPERIMENTAL
Intervention: p24-VLP (500 or 1,000 micrograms)
Number of subjects: 8
Study 9075480 — intervention group
Group type: EXPERIMENTAL
Intervention: p24-VLP (highest dose)
Number of subjects: 8
Study 9075480 — intervention group
Group type: EXPERIMENTAL
Intervention: p24-VLP
Number of subjects: 8
Study 8396320 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir, 800 mg four times daily
Number of subjects: 21
Study 8396320 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir, 800 mg four times daily + IVIG, 300 mg/kg every 2 weeks for six doses
Number of subjects: 21
Study 8396320 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 21
Study 3530643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (400 micrograms)
Number of subjects: 18
Study 3530643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3530643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 18
Study 11280632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracatheter nitroglycerin (NTG) infusion at 0.1 mcg x kg x min in 5% dextrose
Number of subjects: 44
Study 11280632 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only 5% dextrose
Number of subjects: 44
Study 31144547 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally obese participants
Number of subjects: 1358
Study 31144547 — intervention group
Group type: COMPARATOR
Intervention: Non-obese controls
Number of subjects: 1358
Study 29337906 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific collagen peptides (SCP) 5 g daily for 12 months
Number of subjects: 131
Study 29337906 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 131
Study 27553375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir + Ribavirin
Number of subjects: 1952
Study 27553375 — intervention group
Group type: COMPARATOR
Intervention: Illicit drug use during therapy
Number of subjects: 1952
Study 24641790 — intervention group
Group type: EXPERIMENTAL
Intervention: QiShenYiQi dripping pills, Tongxinluo placebo and routine medication
Number of subjects: 160
Study 24641790 — intervention group
Group type: COMPARATOR
Intervention: Tongxinluo capsules, QiShenYiQi placebo and routine medication
Number of subjects: 160
Study 22607134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (prednisone, azathioprine, and NAC)
Number of subjects: 155
Study 22607134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 22607134 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC alone
Number of subjects: 155
Study 21167397 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 14
Study 17958153 — intervention group
Group type: EXPERIMENTAL
Intervention: dynQuest software for conducting PC- and Web-based trials
Number of subjects: 0
Study 16219883 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg once daily)
Number of subjects: 7599
Study 11856076 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole once daily
Number of subjects: 70
Study 11856076 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole once daily
Number of subjects: 70